Clinical trials 22. November 2012
Cardio3 starts Phase III
.... Cardio3 tested its treatment in Phase II between 2009 and 2010 in multiple clinical sites in Belgium, Serbia and Switzerland... more
Search
http://87.106.61.40:13080/rest_search_lbw/api/search/?q=Switzerland%2CSchweiz&website=ebsin&type=Nachrichten&resultsize=10&resultpage=4&sort_by=date&order_by=desc269 items found for your query "Switzerland,Schweiz"
Business 19. November 2012
Biopharma: M&A activity slows
19.11.2012 - Big Pharma has spent less money on M&A this year than in 2011, a new report from Deloitte Recap reveals. Last year, only US$245bn were spent on acquisitions in the life sciences field, according to the... more
Business 31. October 2012
Copycats attack Abbott's Humira
31.10.2012 - With AET Biotech Ltd. and BioXpress SA, two new players join the queue of Humira copycats. The two partners pool their expertise in the manufacturing of biologicals and in development and marketing. The TNF-alpha blocker is... more
Business 29. October 2012
€17m for pan-European PPP
29.10.2012 - It is a significant upgrade for Italian basic research: British-Swiss Shire collaborates with Telethon Foundation on rare disease drugs. It is a company first for British Shire Pharmaceuticals plc. Despite having had strong ties with academia... more
Pharma 24. October 2012
PAH market narrows
24.10.2012 - The competition for PAH treatments will become fierce. Actelion and Bayer both plan to market new treatments for this rare disease. Good news for PAH (pulmonal arterial hypertension) patients: two new drugs are planned for market release. The... more
16. October 2012
Distribution expert
... Anagnostic’s hybcell technology in Germany, Switzerland and Austria. more
Business 15. October 2012
€6m to fight a fatal disease
.... The consortium leader, however, is based in Switzerland. Novimmune SA from Geneva is the originator of the treatment option in question: NI-0501... more
Clinical Trials 2. October 2012
Major success for T-DM1
02.10.2012 - Roche's trastuzumab emtansine (T-DM1) appears to keep its promises. The armed antibody significantly extended overall survival in breast cancer patients. Roche presented the latest big pack of Phase III data for T-DM1 at the ESMO conference... more
Business 23. September 2012
Syngenta is on a shopping spree
24.09.2012 - Syngenta is set to buy two biotech companies: The Swiss firm is willing to pay up about €500m for seed maker Devgen NV and Pasteuria Biosciences. Syngenta announced an offer to acquire all outstanding shares of... more
Business 23. September 2012
Syngenta is on a shopping spree
24.09.2012 - Syngenta is set to buy two biotech companies: The Swiss firm is willing to pay up about €500m for seed maker Devgen NV and Pasteuria Biosciences. Syngenta announced an offer to acquire all outstanding shares of... more
Previous page 4/27 Next page
© 2007-2013 BIOCOM
http://www.eurobiotechnews.eu/service/suche-ebsin.html?tx_lbwsearch_pi1%5Bq%5D=Estonia&tx_lbwsearch_pi1%5BsortOrder%5D=asc&tx_lbwsearch_pi1%5Bpage%5D=2
